We further examined the combination of MS023 and the PARP inhibitor BMN-673 (Talazoparib), and observed strong synergistic interaction at low nM concentrations in MTAP-negative A549, SK-LU-1 and HCC4006 NSCLC cells. Here, PARP1 is linked to non-small cell lung carcinoma.